AXIL Brands has outperformed its sub-industry despite a challenging first quarter with 11.2% revenue decline. The newly launched XCOR II earbuds show promise with $3.6 million in initial orders, while improved liquidity ($7.9 million cash, no debt) and a discounted valuation (9.54X EV/EBITDA) provide support. However, analysts recommend holding rather than buying, citing the need for sustained demand demonstration and recurring cash generation before confirming a durable recovery.

National Vision Holdings (EYE) is highlighted as a stock to watch with a Zacks Rank #2 (Buy) rating and a VGM Score of B. The optical retailer has attractive valuation metrics with a forward P/E ratio of 17.06 and a Value Style Score of A. Four analysts revised earnings estimates upward in the last 60 days, with the consensus estimate increasing to $0.98 per share for fiscal 2026, and the company boasts an average earnings surprise of +52.5%.

National Vision Holdings (EYE) beat Q2 2026 earnings and revenue estimates with adjusted EPS of 25 cents (up 38.9% YoY) and revenues of $498.81 million (up 2.5% YoY). The company raised its 2026 profit outlook, lifting the lower end of adjusted EPS guidance to 94 cents from 85 cents. However, shares have underperformed the S&P 500 by 10.1% since the earnings release, and analyst estimates have shifted downward by 40% following the report. Despite mixed store performance across brands, National Vision maintains a Zacks Rank #2 (Buy) rating.

A comparison of two Consumer Products - Staples stocks reveals that National Vision (EYE) offers better value than Colgate-Palmolive (CL). EYE has a Zacks Rank of #2 (Buy) with improving earnings outlook, a lower forward P/E of 17.51, and a Value grade of B. CL has a Zacks Rank of #3 (Hold), higher forward P/E of 22.74, and a Value grade of D, making EYE the superior value option.

Bain Capital Public Equity acquired 199,934 shares of National Vision Holdings, representing a $5.84 million investment in the optical retail sector. The stock has performed well in 2025, with a 136% year-to-date return, and the company is focusing on cost-cutting and expansion strategies.

National Vision Holdings Inc (EYE) has seen a surge in its stock price after a strong earnings report and a rare double upgrade from Bank of America. The company's strategic initiatives and focus on higher-value customer segments have driven the turnaround, making it a stock to watch for potential long-term gains.

Boston Scientific Corporation is scheduled to report its Q2 2024 results on July 24. The company is expected to report revenue growth of around 11.7% and adjusted earnings of 58 cents per share. However, the company may face challenges from a challenging supply environment, rising costs, and healthcare staffing shortages.

National Vision (EYE) continues to execute core growth initiatives and further invest in strengthening competitive advantages.

National Vision (EYE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

National Vision (EYE) delivers improved revenues in the first quarter of 2024 in a challenging macro environment.

National Vision (EYE) delivered earnings and revenue surprises of 7.14% and 2.68%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Jushi Holdings Inc. (JUSHF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.